Validité des données périnatales issues du PMSI : comparaison avec les données de l’enquête nationale périnatale 2010

Quantin, Catherine; Cottenet, Jonathan; Vuagnat, Albert; Benzenine, Éric; Fresson, Jeanne; Prunet, C.; Mouquet, Marie-Claude; Grémy, Isabelle; Gouyon, Jean‐Bernard; Blondel, Béatrice

doi:10.1016/j.respe.2013.01.007

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prospective payment is directly linked to the coding process leading to optimize this latter. Nevertheless the high exhaustiveness and quality of information (including some medical information) allows using the PMSI database to estimate various indicators by disease, like the number of patients hospitalized annually, the number of stays per patient and the total cost of hospitalization [ 24 – 26 ]. Using hospitals and death records generate limitations: codes were not necessarily accurate; i.e., misclassification or diagnosis errors by coding as a different herpes [ 41 ], under reporting of pre-existing conditions such as stroke [ 42 ]; inadvertent omissions, the unavailability of medical records to certifying physician and difficulties in determining the underlying cause of death and hospitalization when several disease processes were involved [ 43 , 20 ].…”

Section: Discussionmentioning

confidence: 99%

Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France

Blein¹,

Gavazzi

Pocard

et al. 2015

BMC Infect Dis

View full text Add to dashboard Cite

BackgroundThe objectives of this study were to describe hospital stays related to HZ and to evaluate the direct and indirect cost of hospitalizations due to HZ among patients aged over 50 years.MethodsThe hospitalizations of people aged over 50 years were selected from the French national hospital 2011 database (PMSI) using ICD-10 diagnosis codes for HZ.Firstly, stays with HZ as principal or related diagnostic were described through the patient characteristics, type of hospitalization and the related costs. Secondly, a retrospective case–control analysis was performed on stays with HZ as comorbidity in 5 main hospitalizations causes (circulatory, respiratory, osteo-articular, digestive systems and diabetes) to assess the impact of HZ as co-morbidity on the length of stay, mortality rate and costs.ResultsIn the first analysis, 2,571 hospital stays were collected (60 % of women, mean age: 76.3 years and mean LOS: 9.5 days). The total health assurance costs were 10,8 M€. Mean cost per hospital stay was 4,206€. In the second analysis, a significant difference in LOS and costs was shown when HZ was associated as comorbidity in other hospitalization’s causes.ConclusionsHZ directly impacts on the hospital cost. When present as comorbidity for other medical reasons, HZ significantly increases the length of hospital stay with subsequent economic burden for the French Health System.

show abstract